As of November 23, Twitter is no longer enforcing its COVID-19 misinformation policy; CDC awards more than $3 billion to strengthen the public health infrastructure and workforce; lecanemab appears to slow the spread of Alzheimer disease but is linked to multiple adverse events, symptoms, and deaths.
Read More
HDHPs Deter Women From Additional Testing After Abnormal Mammogram, Study Says
November 29th 2022The groups who told researchers they would be more likely to skip additional testing had lower levels of income or education and were more likely to be on Medicaid or be uninsured, among other factors.
Read More
Lack of Knowledge Continues to Influence Delayed Melanoma Diagnosis
November 29th 2022Malignant cutaneous melanoma outcomes were investigated as they relate to diagnosis delay and potential influence from socioeconomic and demographic factors in Brazil, where skin cancer diagnoses represent 30% of all cancer diagnoses.
Read More
US flu hospitalizations increased nearly 30% in the week before Thanksgiving; HHS proposed a rule to align 42 CFR Part 2 privacy protections with existing law to protect patients with substance abuse disorder; New York State saw a decline in opioid prescriptions during the first month of COVID-19 lockdowns.
Read More
Predictors of Severe COVID-19 Infection, Mortality in Patients With MM, AL Identified
November 29th 2022Their findings, say the researchers, offer useful insights into the outcomes and risks of severe disease and mortality in patients who have multiple myeloma (MM) or amyloidosis (AL) with underlying monoclonal gammopathy who contract COVID-19.
Read More
Potential for ICI-Related Arrhythmias Necessitates Recognizing Risk Early
November 29th 2022Researchers pulled data from the FDA’s Adverse Event Reporting System to analyze cardiac arrhythmia–related outcomes among patients on a mono or combination regimen for cancer treatment that included immune checkpoint inhibitors (ICIs).
Read More
Women With CKD Receiving Fertility Treatment Have Similar Birth Rates to Those Conceiving Naturally
November 28th 2022Researchers underscore a need for prospective data, noting that women with chronic kidney disease (CKD) tended to have higher rates of preterm delivery and lower birthweight.
Read More
MDD Treatment Alternatives Explore Potential of Cannabis, Psychedelics
November 28th 2022Stemming from recent data on a potential link between major depressive disorder (MDD) and inflammation, research is starting to turn toward alternatives that can treat the disease through anti-inflammatory effects, including ketamine, cannabinoids, and psychedelics.
Read More
CBD May Improve Neurologic, Cognitive, QOL Outcomes in Sturge-Weber Syndrome
November 28th 2022A small, prospective, open-label trial found evidence of improved quality of life (QOL) and clinical outcomes among patients with treatment-resistant Sturge-Weber syndrome when they were treated with CBD.
Read More
Motor Function Continues to Improve in Second Year of Risdiplam Treatment for SMA
November 26th 2022Detailing findings from the secondary end points of the FIREFISH trial at 24 months, the researchers found that risdiplam treatment was associated with continued improvements in motor function and the achievement of development motor milestones.
Read More
Melissa O'Connor, PhD, MBA, RN, FGSA, FAAN, endowed professor in community and home health nursing, M. Louise Fitzpatrick School of Nursing, Villanova University, and director, Gerontology Interest Group, addressed barriers related to access, cost, and knowledge impeding technology use in home health.
Watch
Empagliflozin Has Similar Efficacy Across Subgroups, More Data Needed in CKD: Dr Jennifer Green
November 26th 2022Data on empagliflozin in chronic kidney disease (CKD) showed the drug had similar efficacy across subgroups, but more data is needed to really understand the benefit of the drug in CKD, said Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator.
Watch
Driving Biosimilar Uptake in Rheumatology, Biosimilar-to-Biosimilar Switching: ACR Abstracts
November 26th 2022Abstracts show that institutions can make internal changes to drive the use of biosimilars and that successful biosimilar-to-biosimilar switching is based on patient-related factors.
Read More